Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Aptus Capital Advisors LLC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aptus Capital Advisors LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 9.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,240 shares of the pharmaceutical company's stock after purchasing an additional 2,072 shares during the period. Aptus Capital Advisors LLC's holdings in Vertex Pharmaceuticals were worth $11,752,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of VRTX. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $31,000. Mpwm Advisory Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $40,000. Minot DeBlois Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $44,000. Finally, SJS Investment Consulting Inc. raised its position in shares of Vertex Pharmaceuticals by 46.2% in the first quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company's stock valued at $46,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on VRTX shares. Canaccord Genuity Group cut their price objective on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald cut their price objective on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an "outperform" rating in a research report on Tuesday, August 5th. Stifel Nicolaus dropped their price target on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research report on Tuesday, August 5th. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $503.00 price target (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $497.10.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock traded up $3.10 on Thursday, hitting $397.46. The stock had a trading volume of 1,851,693 shares, compared to its average volume of 2,487,458. The firm has a market capitalization of $101.90 billion, a price-to-earnings ratio of 28.41 and a beta of 0.44. The stock's 50 day moving average is $440.20 and its 200-day moving average is $462.13. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the prior year, the firm posted ($12.83) EPS. The firm's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by company insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.